Tirzepatide During Pregnancy: The Guidance You Need

Step 1, Stop as soon as you know, and tell your prescriber the same day

If you discover you are pregnant while taking tirzepatide, the first practical step is to stop the injections and contact your prescriber or GP that day. Do not wait for your next scheduled dose. The NHS tirzepatide medicines page states clearly that tirzepatide should not be used in pregnancy, and the medicine's own patient information leaflet reinforces this. You do not need to panic, but you do need to act promptly.

It is worth checking whether your next pen is due within the next day or two, if so, set it aside and make the call first. That thirty-second check could prompt an earlier conversation that matters.

Your prescriber will want to know how far along the pregnancy is and which dose you were on. If you have been taking tirzepatide through a private service like nume, contact our clinical team via the aftercare channel; if you are under NHS care, call your GP. Either way, your maternity team should also be informed so it goes into your pregnancy notes.

Step 2, Understand why the guidance exists, even when your weight history is complicated

There are no controlled human studies of tirzepatide in pregnancy. The guidance not to use it comes from animal reproductive studies, which raised concerns about foetal development at doses comparable to those used in people, combined with the standard principle that medicines without adequate pregnancy safety data are avoided unless there is no alternative and the benefit clearly outweighs risk. For a weight-management medicine, that threshold is not met.

Obesity itself carries real risks in pregnancy, higher rates of gestational diabetes, pre-eclampsia and delivery complications are well documented. Stopping tirzepatide does not erase those risks. That is exactly why the conversation with your maternity team and your GP matters: they can help you manage weight and metabolic health through pregnancy using approaches that are appropriate for that stage of life. Our page on tirzepatide effects on pregnancy explores this in more detail, and NHS England's guidance on weight-management injections addresses this directly, noting that pregnancy is a specific situation requiring specialist input rather than continued treatment.

Breastfeeding sits in the same category: tirzepatide is not recommended while breastfeeding, because it is not known whether the medicine passes into breast milk or what effect that might have on a baby.

Step 3, Plan ahead if you are thinking about conceiving

If you are not yet pregnant but are planning to try, this is the stage where a proactive conversation with your prescriber pays off most. There is a recommended period between stopping tirzepatide and trying to conceive; your prescriber will advise on the right interval for your situation based on how long you have been on treatment and which dose you have reached. Starting that conversation before you try to conceive (rather than after a positive test) gives you more options and more time.

Contraception is a related practical concern. Women taking tirzepatide who use the combined oral contraceptive pill are advised to add a barrier method for the first four weeks of starting treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying and may reduce pill absorption during those windows. Our guide to Mounjaro during pregnancy covers the contraception detail in full, including the specific NHS guidance on which methods are less affected, and if you want to understand the broader picture of how this medicine interacts with pregnancy planning, our dedicated page on Mounjaro and pregnancy brings together the key questions people ask before they start trying to conceive.

If you have questions about your individual circumstances, our prescribers are available through the aftercare channel seven days a week, though any decision about stopping or continuing treatment in the context of pregnancy should always involve your GP and, once pregnant, your maternity team.

Step 4, Returning to treatment after pregnancy or breastfeeding

Tirzepatide is not a permanent door that closes because of pregnancy. Once you have finished breastfeeding and your GP or specialist confirms it is appropriate to restart, a fresh clinical assessment through a regulated service is the route back in. That assessment will look at your current BMI, any conditions that have changed during pregnancy, and whether tirzepatide or another licensed treatment remains the right fit.

The wider question of weight management after having a baby is one many people find complicated, and if you found yourself in the position of having been pregnant on tirzepatide, our dedicated page covers what that experience typically involves and what to expect next. For those who want a broader overview before restarting, our page on pregnancy and tirzepatide brings together the key clinical considerations in one place. The evidence behind GLP-1 and dual-agonist medicines continues to grow, and the Mounjaro overview gives a grounded picture of what the evidence says, without the hype. If you are not sure where to start, our free consultation is the first step, a GPhC-registered prescriber reads every response personally and will tell you plainly whether treatment is appropriate for you right now. No algorithm, no automated decision.